摘要
本实验室前期构建了具有标记特征的腺病毒/甲病毒复制子嵌合载体猪瘟疫苗rAdV-SFV-E2,效力评价结果表明该嵌合疫苗的免疫原性与C株相当,并且能够完全提供对猪瘟病毒(CSFV)强毒石门株的攻毒保护。为进一步确定该疫苗的免疫效力是否受其母源抗体(MDA)的干扰及制定合理有效的免疫程序,本研究将rAdV-SFV-E2疫苗株免疫妊娠期的母猪后检测其抗体诱导水平,然后将该疫苗株免疫具有其母源抗体的30日龄新生仔猪及无母源抗体仔猪(n=4),攻毒后,监测所有仔猪的抗体水平、临床症状、病毒血症、病理学等。结果显示,有无母源抗体的仔猪均能够产生高水平的特异性E2抗体及抗CSFV的中和抗体,而且攻毒后未出现猪瘟特异性临床症状,包括发热、食欲减退、腹泻及死亡等;对照组仔猪均出现了明显的临床症状,其死亡率为100%。本研究证明rAdV-SFV-E2疫苗的免疫效力未受其母源抗体的显著干扰,免疫30日龄的仔猪后能够完全抵抗致死性CSFV强毒石门株的攻击。
Previously, we generated an adenovirus/alphavirus replicon chimeric vectored vaccine rAdV-SFV-E2, the efficacy experiment showed that it induced E2-specific antibodies comparable to C-strain and provided complete protection against challenge with the lethal classical swine fever virus （CSFV） Shimen strain. In order to further determine whether the immune efficacy of rAdV-SFV-E2 was affected by maternally derived antibodies （MDA）, and developed the reasonable and effective immune schedule for piglets. In this study, gestation sows vaccinated with rAdV-SFV-E2 and the E2-specific antibodies level were monitored, and the 30 day-old piglets （n=4） with presence or absence of MDA immunized with rAdV-SFV-E2. Subsequently, the antibodies level, clinical signs, viremia and pathology were monitored in all piglets after challenge. The results showed that all the immunized piglets were able to induce high-level CSFV E2-specific antibodies and anti-CSFV neutralizing antibodies and did not exhibit any clinical signs. The piglets in the control group showed severe clinical signs and died at 12 days post-challenge （dpc）.This study demonstrates that the immune efficacy of rAdV-SFV-E2 is not interfered by MDA, and completely protects the vaccinated piglets from CSFV infection.
出处
《中国预防兽医学报》
CAS
CSCD
北大核心
2016年第6期484-488,共5页
Chinese Journal of Preventive Veterinary Medicine
基金
2014年哈尔滨市科技创新人才专项资金项目-青年后备人才计划(2014RFQYJ126)
关键词
猪瘟
嵌合载体疫苗
免疫效力
母源抗体
classical swine fever
chimeric vectored vaccine
immune efficacy
maternally derived antibodies
